Oxlumo Injection Dosage
Generic name: lumasiran 94.5mg in 0.5mL
Dosage form: injection, solution
Medically reviewed by Drugs.com. Last updated on Nov 24, 2020.
Recommended Dosage
The recommended dosing regimen of OXLUMO consists of loading doses followed by maintenance doses administered subcutaneously as shown in Table 1.
Dosing is based on actual body weight.
Body Weight | Loading Dose | Maintenance Dose (begin 1 month after the last loading dose) |
---|---|---|
Less than 10 kg | 6 mg/kg once monthly for 3 doses | 3 mg/kg once monthly |
10 kg to less than 20 kg | 6 mg/kg once monthly for 3 doses | 6 mg/kg once every 3 months (quarterly) |
20 kg and above | 3 mg/kg once monthly for 3 doses | 3 mg/kg once every 3 months (quarterly) |
Administration Instructions
OXLUMO is intended for subcutaneous use and should be administered by a healthcare professional.
Visually inspect the drug product solution. Do not use if it contains particulate matter or if it is cloudy or discolored. OXLUMO is a sterile, preservative-free, clear, colorless-to-yellow solution. It is supplied in a single-dose vial, as a ready-to-use solution that does not require additional reconstitution or dilution prior to administration.
- Use aseptic technique.
- Divide injection volumes greater than 1.5 mL equally into multiple syringes.
- For volumes less than 0.3 mL, a sterile 0.3-mL syringe is recommended. If using a 0.3 mL (30 unit) insulin syringe, 1-unit markings indicate 0.01 mL.
- Administer subcutaneous injection into the abdomen, thigh, or the side or back of the upper arms. Rotate injection sites. Do not inject into scar tissue or areas that are reddened, inflamed, or swollen.
- If injecting into the abdomen, avoid the area around the navel.
- If more than one injection is needed for a single dose of OXLUMO, the injection sites should be at least 2 cm apart.
- Discard unused portion of the drug.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.